Hetero

About Us
Back
About Us
We are inspiring human belief in a healthier world
Company
Our founding mission is to make highly quality medicines affordable and accessible to the world
Who we are
30 years of Service in the pharmaceutical industry, backed by proven track record in R&D excellence
Leadership
Our mission to enable access to affordable medicines and improve lives flow from the top
Presence
Expanding our presence to serve more people and create meaningful impact
Milestones and Awards
Being acknowledged for our efforts motivates our entire team
Focus Areas
Back
Focus Areas
Our expertise across APIs, global generics, biosimilars and custom pharmaceutical services is secured by a strong R&D backbone
Overview
We have steadily invested in a wide range of innovations to make our product portfolio diverse and differentiated in a competitive market
APIs
The path to serving patients better
Global generics
World-class and differentiated portfolio in chronic therapy areas
Biosimilars
Achieving a sustainable health equity
CPS
Fully integrated services across the value chain
Global Access
Committed to transforming standards of care
Key Therapies
Researching areas of unmet medical need
Expertise
Back
Expertise
Our expertise rest on the pillars of our advanced R&D capabilities, world-class manufacturing facilities, our long legacy of trust and our partnerships
Overview
Research excellence for us means to invest in the future of health for the world
Research & Development
We invest in cutting edge research to develop new cures for challenging diseases
Global Manufacturing Facilities
Built to world-class standards, our facilities enable us to produce high-quality and affordable medicines
Quality Focus
Legacy of trust
Partnerships
Growing better, together
Responsibility
Back
Responsibility
We are committed to making a positive impact by contributing to healthy communities and leading a responsible business
Overview
Aiming for a sustainable environment
Environment, Health & Safety
A constant focus on sustainable environment with focus on health and safety
Community
A steadfast commitment to enable communities
Sustainability Reporting
Hetero aims to report comprehensively and transparently for all stakeholders
News and Media
Back
News and Media
Find range of resources including press releases, featured stories and information on social media channels
Overview
Access our latest press releases and resources for News and Media section
Featured Stories
Discover the stories that enumerate the way we understand disease and develop medicines
Newsroom
Latest media releases and statements in the Hetero newsroom
Press Kit
Browse and download multimedia resources for use
Notices
Notices

COVID-19
Careers
Contact Us

Press Releases

2022

India, Hyderabad; 26 December, 2022
Hetero’s ‘NIRMACOM’ is world’s first generic version of COVID-19 oral drug ‘PAXLOVID’ to receive WHO Prequalification
India, Hyderabad; 17 oct, 2022
Hetero acquires manufacturing plant at Penjerla in Telangana, India
India, Hyderabad; 11 May, 2022
Hetero unveils new logo and corporate brand identity
India, Hyderabad; 21 March, 2022
Hetero receives CDSCO approval to manufacture Sputnik Light vaccine for sale in India
India, Hyderabad; 17 March, 2022
Hetero enters into a voluntary licensing agreement with MPP to expand access of nirmatrelvir & ritonavir generics for COVID-19 treatment in 95 countries.
India, Hyderabad; 19 February, 2022
Hetero presents positive results from Molnupiravir Phase III Studies at CROI 2022

2021

India, Hyderabad; 28 December, 2021
Hetero announces approval and launch of Movfor (Molnupiravir 200 mg) to treat high-risk adult patients with COVID-19.
India, Hyderabad; 28 December, 2021
Hetero Announces Interim Clinical Results from Phase III Clinical Trials of Molnupiravir conducted in India.
India, Hyderabad; 06th September, 2021
Hetero’s Biosimilar Version of Tocilizumab (Tocira) receives Emergency Use Authorization (EUA) from DCGI for the treatment of Covid-19 in hospitalized adults
India, Hyderabad, 27th April 2021
Hetero enters into a voluntary licensing agreement with MSD for the manufacturing and distribution of ‘Molnupiravir’, an investigational Oral Therapeutic for the treatment of Covid-19

2020

Moscow, Russia/Hyderabad, India, November 27, 2020
Hetero RDIF Sputnik V Vaccine
South Africa, Johannesburg, 26th August 2020
Hetero Remdesivir South Africa
Hyderabad, India; 29th July 2020
Hetero Favivir India
Hyderabad, India; 24th June 2020
Hetero Healthcare Covifor Supply
Hyderabad, India; 21th June 2020
Hetero Covifor launch India
India, Hyderabad, 13th May 2020
Hetero Licensing Gilead
India, Hyderabad, 30th March 2020
Hetero Covid-19 Telangana Govt

2019

India, Hyderabad, 17th December 2019
Hetero Taffic Launch Bictegravir
India, Hyderabad, 11th January 2019
Hetero Lapatinib Hertab
India, Hyderabad, 2nd January 2019
Hetero Tarbis Farma Acquisition

2018

India, Hyderabad, 27th February 2018
Hetero Tafero EM India
India, Hyderabad, 3rd January 2018
Hetero Adalimumab Mabura

2017

India, Hyderabad, 14th November 2017
Hetero Darunavir Ritonavir India
India, Hyderabad, 5th May, 2017
Hetero Sofosbuvir Velpatasvir India

2016

India, Hyderabad, 27th June 2016
Hetero Bevacizumab India

2015

India, Hyderabad, December 14th, 2015
Hetero Daclatasvir India
India, Hyderabad, December 8th, 2015
Hetero Ledipasvir Sofosbuvir India
India, Hyderabad, 3rd August 2015
Hetero Biosimilar Rituximab India
India, Hyderabad, 7th April 2015
Hetero Sofovir India

2014

India, Hyderabad, 15th September 2014
Hetero Sofosbuvir Licensing agreement

Explore more

Know more about us through our Press Kit

Caution Notice

Please beware of fake online pharmacies. Kindly note that Hetero does not engage in any form of online distribution or retailing of medicines. Hetero and its group subsidiaries supply the products worldwide, only through their exclusive distribution networks.